Approved: 4 Oct 2017. Last amended: 4 Oct 2017.

8.1 Cytotoxic drugs

Not currently included in Joint Formulary

8.2 Drugs affecting the immune response

Not currently included in Joint Formulary

8.3 Sex hormones and hormone antagonists in malignant disease

8.3.1 Oestrogens

Not currently included in Joint Formulary

8.3.2 Progestogens

Not currently included in Joint Formulary

8.3.3 Androgens

Not currently included in Joint Formulary

8.3.4 Hormone antagonists

8.3.4.1 Breast Cancer

Not currently included in Joint Formulary

8.3.4.2 Gonadorelin analogues

Recommended

  • Triptorelin (Decapeptyl® SR)

    3mg, 11.25mg, 22.5mg (22.5mg IM 6 monthly injection preferred in Primary Care)

  • Alternative

  • Leuprorelin (Prostap®)

    3.75mg, 11.25mg

  • Goserelin (Zoladex®)

    3.6mg, 10.8mg

  • 8.3.4.3 Anti-androgens

    Recommended

  • Bicalutamide
  • Alternative

  • Cyproterone
  • Specific Indication

  • Abiraterone
    • castration-resistant metastatic prostate cancer, as per NICE TA259
    • metastatic hormone-relapsed prostate cancer before chemotherapy is indicated, as per NICE TA387
    • newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, as per NICE TA721
  • Enzalutamide
    • metastatic hormone relapsed prostate cancer previously treated with a docetaxel containing regimen, as per NICE TA316
    • metastatic hormone-relapsed prostate cancer before chemotherapy is indicated, as per NICE TA377
    • hormone-sensitive metastatic prostate cancer, as per NICE TA712
  • 8.3.4.4 Gonadotrophin-releasing hormone antagonists

  • Degarelix

    Advanced hormone-dependent prostate cancer in people with spinal metastases, as per NICE TA404

  • 8.3.4.5 Somatostatin analogues

    Not currently included in Joint Formulary

    BEST CARE FOR EVERYONE